Work

An orally bioavailable allele-selective mutant ATXN1 degrader ameliorates motor and cognitive deficits in a humanized SCA1 knock-in model

Year: 2026
Type: preprint
Abstract: Spinocerebellar ataxia type 1 (SCA1) is a monogenic fatal neurodegenerative disorder that currently has no disease-modifying therapies. SCA1 is mainly driven by the accumulation of mutant Ataxin-1 protein (mATXN1) containing an expanded polyglutamine (polyQ) stretch, whereas its wild-type version (wtATXN1) has important neuronal and molecular functions. Similar scenarios apply to other polyQ diseases, such as Huntington’s disease (HD) and several other types of SCAs. Thus, allele-selective mATXN1 lowering with orally available small molecule compounds is highly desirable, in order to avoid deleterious consequences of wtATXN1 depletion. Here, we identified the compound 715, a novel oxindole-derived, brain-penetrant, and orally available degrader that lowers both soluble and aggregated mATXN1 in an allele-selective manner. Mechanistically, 715 enhanced proteasomal but not autophagic degradation of mATXN1 by elevating its poly-ubiquitination. A ubiquitin-focused CRISPR screen identified BIRC7 as the primary E3 ligase mediating 715-induced mATXN1 poly-ubiquitination and clearance. Intraperitoneal administration of 715 significantly reduced cerebellar mATXN1 by 40-60% within 10 days and partially rescued motor deficits over 30-day dosing in Atxn1154Q/2Q knock-in mice. To improve translational assessment, we generated and characterized a humanized Atxn1h60Q/2Q knock-in model carrying a clinically representative polyQ length (60Q), in which 715 lowered endogenous mATXN1 and substantially improved motor coordination, spatial learning, and cerebellar Purkinje cell pathology. Notably, a 40-day oral dosing regimen of 715 achieved 30-40% cerebellar mATXN1 clearance and comparable functional rescue with a favorable long-term safety profile, highlighting the translational potential of the allele-selective lowering of mATXN1, even to a modest degree. Together, we identified 715 as an orally active therapeutic lead compound, providing potential new entry points for SCA1 treatment.
Language: English
Open Access status: green
OpenAlex ID: W7236573403
Cites: 51
Cited by:
Related to: 10